
Please try another search
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa S.r.l for production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Maris Hartmanis | 72 | 2015 | Independent Director |
Torbjörn Koivisto | 56 | 2017 | Independent Director |
Anders Bladh | 67 | 2021 | Director |
Robert Molander | 60 | 2022 | Independent Director |
Carl-Johan Spak | 69 | 2015 | Independent Director |
Christine Lind | 51 | 2019 | Independent Director |
Anders Ekblom | 71 | 2021 | Chairman |
Anne Prener | 67 | 2025 | Director |
Markus Haeberlein | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review